Caring for patients with PAH?
Talk to your patients about ILLUMINATE
With limited treatment options and no cure for pulmonary arterial hypertension (PAH), the ILLUMINATE clinical research study is currently underway to investigate potential treatments. Consider the ILLUMINATE as an opportunity for your patients with PAH to access emerging treatments.
ILLUMINATE is a phase 2 clinical study for adults with symptomatic PAH. This study is evaluating the efficacy and safety of an investigational treatment in patients with PAH in addition to their background standard of care therapy for PAH.
ILLUMINATE will last at least 9 months and up to about 2.5 years. Over the course of the study, the investigational treatment or placebo will be administered as an IV infusion given once a month during the Treatment Period. During the Extended Treatment Period, the investigational treatment will be administered as a subcutaneous dose once a week.
Patients are expected to participate in this study for at least 9 months and up to approximately 2.5 years. There will be no cost for the study treatments, visits, tests, or supplies that are required for the study for qualified participants. Reasonable travel costs (like fuel and bus/train tickets) and food costs will be reimbursed.
How can you help?
ILLUMINATE is enrolling approximately 99 people with PAH worldwide. The success of ILLUMINATE depends on physicians to refer potential study participants. Your patients may be eligible if they:
- Are at least 18 years of age
- Have been diagnosed with PAH (WHO functional class II or III)
- Are receiving stable background non-sotatercept standard of care therapy for PAH on a stable dose and regimen for at least 8 weeks prior to screening AND/OR Are receiving a stable sotatercept dose for at least 24 weeks prior to screening
- PVR ≥400 dynes∙sec/cm5 (5 Wood units) based on RHC during the screening period per central reading
Please note: Other protocol-defined inclusion/exclusion criteria apply.
The site study team will check your patient’s full medical history to see if they meet all inclusion criteria and none of the exclusion criteria. Diversity in clinical studies is critical to developing better treatments – help ensure that your patients are represented.
If you have potentially eligible and interested patients, empower them with options and discuss the ILLUMINATE study. You may also contact the nearest study site to refer them.
This clinical research study will use an investigational drug product, the safety and efficacy of which has not been fully evaluated by Regulatory Authorities.
Find a study site near you!
Your patient’s health and safety are our top priorities. We hope you value the impact of this research and will consider referring potential candidates. With your support, we hope to help patients with PAH.
Serbian 
English